Developing “Better Biologics” through “Evergreening “= High Value Proposition

Investment in biologics based medicine is gaining momentum as these drugs offer targeted therapy and often safer treatment options, higher returns on investment and slower erosion of market share post patent expiry compared to small molecule based drugs. First Generation Monoclonal antibody based drugs are the cornerstone of treatment of major diseases (RA, MS, cancers, AMD, etc). As the patents for these 1st generation Mabs are set to expire from 2014 onwards we focus on companies with novel technology platforms…

Continue Reading
Close Menu